Contrasting ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA)

Innate Pharma (NASDAQ:IPHA) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Volatility & Risk

Innate Pharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Insider and Institutional Ownership

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 41.5% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Innate Pharma and ProKidney”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$24.85 million	6.45	-$8.19 million	N/A	N/A
ProKidney	N/A	N/A	-$35.47 million	($0.57)	-3.46

Innate Pharma has higher revenue and earnings than ProKidney.

Profitability

This table compares Innate Pharma and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
ProKidney	N/A	N/A	-8.80%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Innate Pharma and ProKidney, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0	0	1	1	3.50
ProKidney	0	3	2	0	2.40

Innate Pharma presently has a consensus target price of $11.50, indicating a potential upside of 480.81%. ProKidney has a consensus target price of $4.50, indicating a potential upside of 128.43%. Given Innate Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than ProKidney.

Summary

Innate Pharma beats ProKidney on 6 of the 10 factors compared between the two stocks.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.